TARA · Protara Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | Shefferman Jesse |
Director, CEO and President |
Gift↓
|
Common Stock
|
5,000 |
| 2026-06-30 | Shefferman Jesse |
Director, CEO and President |
Gift↓
|
Common Stock
|
7,000 |
| 2026-06-30 | Shefferman Jesse |
Director, CEO and President |
Gift↓
|
Common Stock
|
14,000 |
| 2026-06-30 | Shefferman Jesse |
Director, CEO and President |
Gift↓
|
Common Stock
|
4,000 |
| 2026-06-29 | Shefferman Jesse |
Director, CEO and President |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 to $4.14, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
215,687 |
| 2026-06-29 | Shefferman Jesse |
Director, CEO and President |
Convert↑
|
Common Stock
|
215,687 |
| 2026-06-29 | Shefferman Jesse |
Director, CEO and President |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares underlying the option vested on January 19, 2025 and the remaining shares have vested or will vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Stock Option (Right to Buy)
|
215,687 |
| 2026-06-15 | Huang Jane |
CMO, Hematology |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
31,000 |
| 2026-06-15 | GARCEAU ROGER |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
31,000 |
| 2026-06-15 | Smith Cynthia |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
31,000 |
| 2026-06-15 | Levy Richard S |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
31,000 |
| 2026-06-15 | Solomon Michael Edward |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
31,000 |
| 2026-06-15 | BESHAR LUKE M |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
31,000 |
| 2026-06-15 | Flannelly Barry P |
EVP & General Manager US |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
31,000 |
| 2026-06-15 | SARGEN GREGORY |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
31,000 |
| 2026-06-02 | CONKLING WILLIAM |
Chief Executive Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on June 2, 2025. |
Common Stock
|
6,008 |
| 2026-04-08 | Zummo Jacqueline |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025. |
Common Stock
|
1,134 |
| 2026-04-01 | Zummo Jacqueline |
Chief R&D Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.31, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
22,598 |
| 2026-01-26 | Fabbio Patrick |
CFO & President |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025. |
Common Stock
|
3,261 |
| 2026-01-26 | Fry Hannah |
VP, Controller |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025. |
Common Stock
|
1,457 |
| 2026-01-26 | Zummo Jacqueline |
Chief R&D Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025. |
Common Stock
|
3,724 |
| 2026-01-26 | Shefferman Jesse |
Director, CEO and President |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025. |
Common Stock
|
8,732 |
| 2026-01-20 | Fry Hannah |
VP, Controller |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024. |
Common Stock
|
2,132 |
| 2026-01-20 | Zummo Jacqueline |
Chief R&D Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024. |
Common Stock
|
6,578 |
| 2026-01-20 | Fabbio Patrick |
CFO & President |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2024. |
Common Stock
|
3,063 |
| 2026-01-20 | Shefferman Jesse |
Director, CEO and President |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024. |
Common Stock
|
16,322 |
| 2026-01-16 | Nicacio Leonardo Viana |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Stock Option (Right to Buy)
|
158,000 |
| 2026-01-16 | Fabbio Patrick |
CFO & President |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Stock Option (Right to Buy)
|
175,000 |
| 2026-01-16 | Shefferman Jesse |
Director, CEO and President |
Award↑
Filing footnotes — Common Stock (Direct)
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Common Stock
|
87,000 |
| 2026-01-16 | CONKLING WILLIAM |
Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Common Stock
|
26,000 |
| 2026-01-16 | CONKLING WILLIAM |
Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Stock Option (Right to Buy)
|
158,000 |
| 2026-01-16 | Fabbio Patrick |
CFO & President |
Award↑
Filing footnotes — Common Stock (Direct)
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Common Stock
|
28,000 |
| 2026-01-16 | Nicacio Leonardo Viana |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Common Stock
|
26,000 |
| 2026-01-16 | Zummo Jacqueline |
Chief R&D Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Common Stock
|
30,000 |
| 2026-01-16 | Fry Hannah |
VP, Controller |
Award↑
Filing footnotes — Common Stock (Direct)
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Common Stock
|
9,500 |
| 2026-01-16 | Fry Hannah |
VP, Controller |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Stock Option (Right to Buy)
|
55,000 |
| 2026-01-16 | Shefferman Jesse |
Director, CEO and President |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Stock Option (Right to Buy)
|
524,000 |
| 2026-01-16 | Zummo Jacqueline |
Chief R&D Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Stock Option (Right to Buy)
|
180,000 |
| 2025-06-27 | Shefferman Jesse |
Director, CEO and President |
Gift↓
|
Common Stock
|
10,200 |
| 2025-06-27 | Shefferman Jesse |
Director, CEO and President |
Gift↓
|
Common Stock
|
3,367 |
| 2025-06-26 | Shefferman Jesse |
Director, CEO and President |
Gift↓
|
Common Stock
|
1,700 |
| 2025-06-26 | Shefferman Jesse |
Director, CEO and President |
Gift↓
|
Common Stock
|
3,400 |
| 2025-06-24 | Shefferman Jesse |
Director, CEO and President |
Gift↓
Filing footnotes — Common Stock (Direct)
On June 24, 2025, the reporting person transferred 300,000 shares of common stock to The Samhold Family Trust for no consideration. Members of the reporting person's immediate family are the sole beneficiaries of the trust and a member of the reporting person's immediate family serves as a trustee thereof. The reporting person remains the beneficial owner of the securities held by the trust. |
Common Stock
|
300,000 |
| 2025-06-12 | GARCEAU ROGER |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
24,000 |
| 2025-06-12 | Flannelly Barry P |
EVP & General Manager US |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
24,000 |
| 2025-06-12 | Levy Richard S |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
24,000 |
| 2025-06-12 | Huang Jane |
CMO, Hematology |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
24,000 |
| 2025-06-12 | Solomon Michael Edward |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
24,000 |
| 2025-06-12 | Smith Cynthia |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
24,000 |
| 2025-06-12 | SARGEN GREGORY |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Stock Option (Right to Buy)
|
24,000 |